99mTc-甲氧基异丁基异腈在肾脏肿块中的摄取与线粒体含量及多药耐药泵表达的相关性
研究对50个术前行99mTc-sestamibi SPECT/CT的肾脏肿块进行免疫组化检测线粒体含量与MDR1/P-gp表达,发现HOCT均呈强线粒体染色合并低MDR1染色,透明细胞肾细胞癌多呈低线粒体和高MDR1染色,除嫌色细胞肾细胞癌外染色模式可预测99mTc-sestamibi摄取。
要点
- 6/6(100%)HOCT呈强线粒体染色合并低MDR1染色,2/2(100%)HOCT同样呈此模式。
- 透明细胞肾细胞癌多数呈低线粒体染色(14/26,54%)和高MDR1染色(18/26,69%)。
- 除嫌色细胞肾细胞癌外,染色模式可靠预测99mTc-sestamibi摄取。
核心结论
- 高线粒体含量且MDR泵表达活性相对较低的肾脏肿瘤会摄取99mTc-sestamibi,有助于准确诊断包括嗜酸细胞瘤和HOCT在内的良性/惰性肿瘤类别。
- 当MDR活性超过线粒体含量时,肿瘤在99mTc-sestamibi SPECT/CT上表现为冷区,有助于高置信度诊断肾细胞癌。
研究设计与样本
- 对50个术前行99mTc-sestamibi SPECT/CT的肾脏肿块进行免疫组化检测线粒体含量和多药耐药泵1(MDR1/P-gp)表达,染色半定量评分,比较不同肾脏肿瘤组织学类型并与99mTc-sestamibi摄取进行相关性分析。
主要发现
- 6/6(100%)HOCT和2/2(100%)HOCT呈强线粒体含量染色合并低MDR1染色。
- 透明细胞肾细胞癌呈相反模式,多数为低线粒体染色(14/26,54%)和高MDR1染色(18/26,69%)。
- 其他肿瘤类型染色模式更多变,但除嫌色细胞肾细胞癌外,染色模式在几乎所有肿瘤中可靠预测99mTc-sestamibi摄取。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 99mTc-sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) has recently been explored for the characterization of indeterminate renal masses. As judged by increased intra-tumoral radiotracer uptake, we have previously reported the excellent diagnostic performance characteristics of this test for identifying benign/indolent oncocytomas and hybrid oncocytic/chromophobe tumors (HOCTs). In this study, we investigated potential molecular mechanisms underlying the discriminatory ability of 99mTc-sestamibi SPECT/CT for renal masses. Fifty renal masses imaged with 99mTc-sestamibi SPECT/CT prior to surgical resection were evaluated by immunohistochemistry for mitochondrial content and expression of the multi-drug resistance pump 1 (MDR1/P-gp). Immunohistochemical staining was scored semi-quantitatively, and results were compared across renal tumor histologies and correlated with 99mTc-sestamibi uptake. RESULTS: In total, 6/6 (100%) and 2/2 (100%) HOCTs demonstrated strong mitochondrial content staining combined with low MDR1 staining. Clear cell renal cell carcinoma showed an opposite pattern with the majority having low mitochondrial (14/26, 54%) and high MDR1 staining (18/26, 69%). Other tumor types were more variable in staining pattern, although the staining pattern reliably predicted 99mTc-sestamibi uptake in almost all tumors except chromophobe renal cell carcinoma. CONCLUSIONS: Our findings confirm that renal tumors with high mitochondrial content and relatively low MDR pump expression activity accumulate 99mTc-sestamibi and allow for the accurate diagnosis of the benign/indolent tumor class that includes oncocytomas and HOCTs. For masses in which MDR activity outweighs the presence of mitochondria, the tumors appear cold on 99mTc-sestamibi SPECT/CT, allowing for high confidence in the diagnosis of renal cell carcinoma.
引用
- Rowe SP, Gorin MA, Solnes LB, et al. Correlation of 99mTc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression. EJNMMI Res. 2017. PMID: 28971329. doi:10.1186/s13550-017-0329-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。